マイクロRNA市場規模、シェア、動向分析レポート:製品・サービス別(装置、消耗品)、用途別(癌、感染症)、最終用途別、地域別、セグメント別予測、2024年~2030年MicroRNA Market Size, Share & Trends Analysis Report By Products & Services (Instruments, Consumables), By Application (Cancer, Infectious Diseases) By End-use, By Region, And Segment Forecasts, 2024 - 2030 マイクロRNA市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界のマイクロRNA市場規模は、2024年から2030年にかけて12.87%のCAGRを記録し、2030年までに36億4000万米ドルに達すると予測... もっと見る
1~3営業日
サマリーマイクロRNA市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界のマイクロRNA市場規模は、2024年から2030年にかけて12.87%のCAGRを記録し、2030年までに36億4000万米ドルに達すると予測されている。同市場の成長を後押ししているのは、新規診断検査や治療薬の開発のための研究開発イニシアティブへの多額の投資であり、臨床試験におけるマイクロRNAの統合の成功も相まって、このような状況が生まれている。現在のバイオテクノロジー産業において、バイオ医薬品部門は重要な役割を果たしている。バイオテクノロジー業界では、研究開発への支出が大幅に増加している。いくつかのバイオ医薬品会社は、RNAベースの治療薬(miRNAとsiRNA)の開発に投資している。主な企業には、Regulus Therapeutics社、Rosetta Genomics社、Alnylam Pharmaceuticals社、miRagen Therapeutics社、Mirna Therapeutics社などがある。 新しい診断テストと治療薬の開発のためのmiRNA研究開発イニシアチブにおける政府資金の増加と相まって、多額の投資が市場の成長を後押しすると予想されています。標的治療薬の開発や創薬ターゲットの同定に向けた革新的なアプローチで市場に参入してきた新規参入企業もいくつかある。例えば、2022年4月にElsevier誌に掲載された論文では、研究者チームが疾患の早期診断のための循環miRNAの臨床的価値を示す現在の大規模コホート研究の概要を提供している。 特に胸部癌のような癌細胞株において、様々なマイクロRNAの腫瘍抑制効果を調査する研究が増加していることが、マイクロRNA研究ツールに対する需要の増加を促している。さらに、miRNAベースの治療薬は様々な疾患の治療において高い可能性を示しており、絶えず進化を続けている。miRNAベースの治療薬を標的細胞に正確に送達することは、臨床応用において依然として大きな課題である。しかし、ナノ粒子ベースの送達システムなど、効率的な送達システムの最近の導入は、この課題の克服に役立つと期待されている。 マイクロRNA市場レポートハイライト - 製品・サービス別では、単離・精製、miRNA cDNA合成、プロファイリング、局在化、定量化、機能解析など幅広いサービスを提供できるサービス分野が2023年に58.8%の高収益シェアで市場を席巻 - 用途別では、miRNAシグネチャーを採用する癌研究への投資が高いことから、2023年に癌分野が最も高い収益シェアを占めた。 - 最終用途別では、バイオテクノロジー・製薬企業分野が2023年に最も高い収益シェアで市場を支配した。これは、最先端の研究へのアクセスや大規模プロジェクトでの共同研究を可能にする研究機関との共同研究やパートナーシップを確立する能力があるためである - 北米は、同地域の主要市場プレイヤーの存在により、2023年の世界産業で優位を占める 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.1.1. Segment Definitions 1.1.1.1. Products & Service Segment 1.1.1.2. Application Segment 1.1.1.3. End-use Segment 1.2. Regional Scope 1.3. Estimates and Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.10. List of Primary Sources 1.11. List of Abbreviations Chapter 2. MicroRNA (miRNA) Market: Executive Summary 2.1. Market Snapshot 2.2. Products and Services Snapshots 2.3. Application and End-use Snapshot 2.4. Competitive Landscape Snapshot Chapter 3. MicroRNA (miRNA) Market Variables, Trends, & Scope 3.1. Market Segmentation and Scope 3.2. Market Lineage Outlook 3.2.1. Parent Market Outlook 3.2.2. Related/Ancillary Market Outlook 3.3. Market Dynamics 3.4. Market Drivers Analysis 3.4.1. Outbreak of COVID - 19 3.4.2. Recent innovation in application of miRNAs 3.4.2.1. Increased adoption for use as a biomarker 3.4.2.2. Therapeutic applications 3.4.3. High investments in miRNA R&D initiatives for development of new diagnostic tests & therapeutics 3.4.4. The success of miRNA in clinical trials 3.4.5. Technological advancements to support nucleic acid studies 3.4.6. Exponentially declining cost of sequencing 3.5. Market Restraint Analysis 3.5.1. High cost associated with microRNA kits and other products 3.5.2. Challenges in handling RNA & in-house development of assays for microRNA detection 3.5.3. Poor reproducibility of research and specificity of products 3.5.4. Limited life science research infrastructure in emerging markets 3.6. Business Environment Analysis 3.6.1. Porter’s Five Forces Analysis 3.6.2. PESTLE Analysis 3.7. COVID-19 Analysis Chapter 4. Products & Services Estimates & Trend Analysis 4.1. MicroRNA (miRNA) Market: Products Movement Analysis 4.2. Instruments 4.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2. Technology 4.2.2.1. Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.2. Real-Time PCR 4.2.2.2.1. Real-Time PCR Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.3. Microarray 4.2.2.3.1. Microarray Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.4. NGS 4.2.2.4.1. NGS Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.5. Others 4.2.2.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3. Workflow 4.2.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.2. Isolation & Purification 4.2.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.3. miRNA cDNA Synthesis 4.2.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.4. Profiling, Localization, & Qualification 4.2.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.5. Functional Analysis & Others 4.2.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.6. Others 4.2.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3. Consumables 4.3.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2. Specimen 4.3.2.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.2. Whole Blood 4.3.2.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.3. Serum 4.3.2.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.4. Plasma 4.3.2.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.5. FFPE 4.3.2.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.6. Fresh Frozen Tissue 4.3.2.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.7. Others 4.3.2.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3. Workflow 4.3.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.2. Isolation & Purification 4.3.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.3. miRNA cDNA Synthesis 4.3.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.4. Profiling, Localization, & Qualification 4.3.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.5. Functional Analysis & Others 4.3.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.6. Others 4.3.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4. Services 4.4.1. Service Type Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.2. Isolation & Purification 4.4.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.3. miRNA cDNA Synthesis 4.4.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.4. Profiling, Localization, & Qualification 4.4.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.5. Functional Analysis 4.4.5.1. Functional Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.6. Others 4.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5. Specimen 4.5.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.2. Whole Blood 4.5.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.3. Serum 4.5.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.4. Plasma 4.5.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.5. FFPE 4.5.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.6. Fresh Frozen Tissue 4.5.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.7. Others 4.5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 5. Application Estimates & Trend Analysis 5.1. MicroRNA (miRNA) Market: Application Movement Analysis 5.2. Cancer 5.2.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.3. Infectious Diseases 5.3.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.4. Immunological Disorder 5.4.1. Immunological Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.5. Cardiovascular Disease 5.5.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.6. Neurological Disease 5.6.1. Neurological Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.7. Others 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 6. End-use Estimates & Trend Analysis 6.1. MicroRNA (miRNA) Market: End-use Movement Analysis 6.2. Biotechnology & Pharmaceutical Companies 6.2.1. Biotechnology & Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.3. Academic & Government Research Institutes 6.3.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.4. Other End-users 6.4.1. Other End-users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Regional Market Snapshot 7.2. North America 7.2.1. North America MicroRNA (miRNA) Market Estimates And Forecast, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. Target Disease Prevalence 7.2.2.5. U.S. MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Target Disease Prevalence 7.2.3.5. Canada MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. Target Disease Prevalence 7.3.2.5. UK MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Target Disease Prevalence 7.3.3.5. Germany MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.4. Spain 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. Target Disease Prevalence 7.3.4.5. Spain MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.5. France 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Target Disease Prevalence 7.3.5.5. France MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.6. Italy 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Target Disease Prevalence 7.3.6.5. Italy MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Target Disease Prevalence 7.3.7.5. Denmark Microrna (Mirna) Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Target Disease Prevalence 7.3.8.5. Sweden MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Target Disease Prevalence 7.3.9.5. Norway MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia-Pacific MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Target Disease Prevalence 7.4.2.5. Japan MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. Target Disease Prevalence 7.4.3.5. China MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. Target Disease Prevalence 7.4.4.5. India MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.5. South Korea 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Target Disease Prevalence 7.4.5.5. South Korea MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Target Disease Prevalence 7.4.6.5. Thailand MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.7. Australia 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. Target Disease Prevalence 7.4.7.5. Australia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Target Disease Prevalence 7.5.2.5. Brazil MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Target Disease Prevalence 7.5.3.5. Mexico MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Target Disease Prevalence 7.5.4.5. Argentina MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. Target Disease Prevalence 7.6.2.5. South Africa MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Target Disease Prevalence 7.6.3.5. Saudi Arabia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. Target Disease Prevalence 7.6.4.5. UAE MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Target Disease Prevalence 7.6.5.5. Kuwait MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.2.1. Acquisition 8.2.2. Product/Service Launch 8.2.3. Partnerships/Collaborations 8.2.4. Others 8.3. Market Position Analysis, 2023 8.4. Company Profiles 8.4.1. Thermo Fisher Scientififc, Inc 8.4.1.1. Company Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. QIAGEN 8.4.2.1. Company Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. Horizon Discovery Group Co. 8.4.3.1. Company Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. NanoString Technologies, Inc 8.4.4.1. Company Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Merck KGaA 8.4.5.1. Company Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. Takara Bio, Inc 8.4.6.1. Company Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. LGC Limited 8.4.7.1. Company Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. BioGenex 8.4.8.1. Company Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. GeneCopoeia, Inc 8.4.9.1. Company Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. New England Biolabs 8.4.10.1. Company Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
SummaryMicroRNA Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.1.1. Segment Definitions 1.1.1.1. Products & Service Segment 1.1.1.2. Application Segment 1.1.1.3. End-use Segment 1.2. Regional Scope 1.3. Estimates and Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.10. List of Primary Sources 1.11. List of Abbreviations Chapter 2. MicroRNA (miRNA) Market: Executive Summary 2.1. Market Snapshot 2.2. Products and Services Snapshots 2.3. Application and End-use Snapshot 2.4. Competitive Landscape Snapshot Chapter 3. MicroRNA (miRNA) Market Variables, Trends, & Scope 3.1. Market Segmentation and Scope 3.2. Market Lineage Outlook 3.2.1. Parent Market Outlook 3.2.2. Related/Ancillary Market Outlook 3.3. Market Dynamics 3.4. Market Drivers Analysis 3.4.1. Outbreak of COVID - 19 3.4.2. Recent innovation in application of miRNAs 3.4.2.1. Increased adoption for use as a biomarker 3.4.2.2. Therapeutic applications 3.4.3. High investments in miRNA R&D initiatives for development of new diagnostic tests & therapeutics 3.4.4. The success of miRNA in clinical trials 3.4.5. Technological advancements to support nucleic acid studies 3.4.6. Exponentially declining cost of sequencing 3.5. Market Restraint Analysis 3.5.1. High cost associated with microRNA kits and other products 3.5.2. Challenges in handling RNA & in-house development of assays for microRNA detection 3.5.3. Poor reproducibility of research and specificity of products 3.5.4. Limited life science research infrastructure in emerging markets 3.6. Business Environment Analysis 3.6.1. Porter’s Five Forces Analysis 3.6.2. PESTLE Analysis 3.7. COVID-19 Analysis Chapter 4. Products & Services Estimates & Trend Analysis 4.1. MicroRNA (miRNA) Market: Products Movement Analysis 4.2. Instruments 4.2.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2. Technology 4.2.2.1. Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.2. Real-Time PCR 4.2.2.2.1. Real-Time PCR Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.3. Microarray 4.2.2.3.1. Microarray Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.4. NGS 4.2.2.4.1. NGS Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.2.5. Others 4.2.2.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3. Workflow 4.2.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.2. Isolation & Purification 4.2.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.3. miRNA cDNA Synthesis 4.2.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.4. Profiling, Localization, & Qualification 4.2.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.5. Functional Analysis & Others 4.2.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.2.3.6. Others 4.2.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3. Consumables 4.3.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2. Specimen 4.3.2.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.2. Whole Blood 4.3.2.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.3. Serum 4.3.2.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.4. Plasma 4.3.2.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.5. FFPE 4.3.2.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.6. Fresh Frozen Tissue 4.3.2.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.2.7. Others 4.3.2.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3. Workflow 4.3.3.1. Workflow Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.2. Isolation & Purification 4.3.3.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.3. miRNA cDNA Synthesis 4.3.3.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.4. Profiling, Localization, & Qualification 4.3.3.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.5. Functional Analysis & Others 4.3.3.5.1. Functional Analysis & Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.3.3.6. Others 4.3.3.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4. Services 4.4.1. Service Type Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.2. Isolation & Purification 4.4.2.1. Isolation & Purification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.3. miRNA cDNA Synthesis 4.4.3.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.4. Profiling, Localization, & Qualification 4.4.4.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.5. Functional Analysis 4.4.5.1. Functional Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.4.6. Others 4.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5. Specimen 4.5.1. Specimen Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.2. Whole Blood 4.5.2.1. Whole Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.3. Serum 4.5.3.1. Serum Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.4. Plasma 4.5.4.1. Plasma Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.5. FFPE 4.5.5.1. FFPE Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.6. Fresh Frozen Tissue 4.5.6.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5.7. Others 4.5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 5. Application Estimates & Trend Analysis 5.1. MicroRNA (miRNA) Market: Application Movement Analysis 5.2. Cancer 5.2.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.3. Infectious Diseases 5.3.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.4. Immunological Disorder 5.4.1. Immunological Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.5. Cardiovascular Disease 5.5.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.6. Neurological Disease 5.6.1. Neurological Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.7. Others 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 6. End-use Estimates & Trend Analysis 6.1. MicroRNA (miRNA) Market: End-use Movement Analysis 6.2. Biotechnology & Pharmaceutical Companies 6.2.1. Biotechnology & Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.3. Academic & Government Research Institutes 6.3.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.4. Other End-users 6.4.1. Other End-users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Regional Market Snapshot 7.2. North America 7.2.1. North America MicroRNA (miRNA) Market Estimates And Forecast, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. Target Disease Prevalence 7.2.2.5. U.S. MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Target Disease Prevalence 7.2.3.5. Canada MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. Target Disease Prevalence 7.3.2.5. UK MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Target Disease Prevalence 7.3.3.5. Germany MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.4. Spain 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. Target Disease Prevalence 7.3.4.5. Spain MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.5. France 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Target Disease Prevalence 7.3.5.5. France MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.6. Italy 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Target Disease Prevalence 7.3.6.5. Italy MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Target Disease Prevalence 7.3.7.5. Denmark Microrna (Mirna) Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Target Disease Prevalence 7.3.8.5. Sweden MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Target Disease Prevalence 7.3.9.5. Norway MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia-Pacific MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Target Disease Prevalence 7.4.2.5. Japan MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. Target Disease Prevalence 7.4.3.5. China MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. Target Disease Prevalence 7.4.4.5. India MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.5. South Korea 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Target Disease Prevalence 7.4.5.5. South Korea MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Target Disease Prevalence 7.4.6.5. Thailand MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.4.7. Australia 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. Target Disease Prevalence 7.4.7.5. Australia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Target Disease Prevalence 7.5.2.5. Brazil MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Target Disease Prevalence 7.5.3.5. Mexico MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Target Disease Prevalence 7.5.4.5. Argentina MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. Target Disease Prevalence 7.6.2.5. South Africa MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Target Disease Prevalence 7.6.3.5. Saudi Arabia MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. Target Disease Prevalence 7.6.4.5. UAE MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Target Disease Prevalence 7.6.5.5. Kuwait MicroRNA (miRNA) Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.2.1. Acquisition 8.2.2. Product/Service Launch 8.2.3. Partnerships/Collaborations 8.2.4. Others 8.3. Market Position Analysis, 2023 8.4. Company Profiles 8.4.1. Thermo Fisher Scientififc, Inc 8.4.1.1. Company Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. QIAGEN 8.4.2.1. Company Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. Horizon Discovery Group Co. 8.4.3.1. Company Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. NanoString Technologies, Inc 8.4.4.1. Company Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Merck KGaA 8.4.5.1. Company Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. Takara Bio, Inc 8.4.6.1. Company Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. LGC Limited 8.4.7.1. Company Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. BioGenex 8.4.8.1. Company Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. GeneCopoeia, Inc 8.4.9.1. Company Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. New England Biolabs 8.4.10.1. Company Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
Grand View Research社の生物分野での最新刊レポート
本レポートと同じKEY WORD(instruments)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |